^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CDK2 amplification

    i
    Other names: CDK2, Cyclin-dependent kinase 2
    Entrez ID:
    1017
    Related biomarkers:
    Expression
    over1year
    Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer. (PubMed, Biochim Biophys Acta Mol Cell Res)
    Selective CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, have been approved in combination with hormone therapy for the treatment of patients with HR+, HER2-negative advanced or metastatic breast cancer (mBC). Identifying the different mechanisms by which resistance to CDK4/6 inhibitors occurs may help to design new treatment strategies to improve patient outcomes. This review presents the currently available knowledge on the mechanisms of resistance to CDK4/6 inhibitors, explores possible treatment strategies that could overcome this therapeutic problem, and summarizes relevant recent clinical trials.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor) • CDK2 (Cyclin-dependent kinase 2)
    |
    HR positive • HER-2 negative • CCNE1 amplification • CDK4 amplification • CDK2 amplification • CDK6 amplification
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)